Evidence map›Paper›PMID 18426856›Full record

ArticleMolecular pharmacology2008

Selective killing of Smad4-negative tumor cells via a designed repressor strategy.

Vidula Dixit, Rudy L Juliano

Abstract read
In one paragraph

Article in Molecular pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Vidula DixitDepartment of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina 27599-7365, USA.
Rudy L Juliano
University of North Carolina at Chapel Hill · US

Funding

TRANSPORT AND DELIVERY OF ANTISNESE OLIGONUCLEOTIDESP01GM059299 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, RUDOLPH · 2000 to 2010
$11.7M
TARGETING CANCER CELL DNA WITH COMBINATORIAL LIGANDSR01CA077340 · NCI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, RUDOLPH · 1998 to 2005
$1.5M
NCI NIH HHS CA77340NCI NIH HHS R01 CA077340NIGMS NIH HHS GM59299NIGMS NIH HHS P01 GM059299
6 · The paper itself

Abstract

Smad4 is a key tumor suppressor that is frequently deleted or inactive in pancreatic and colon tumors. In this report, we describe an approach for attaining selective killing of Smad4-deficient tumor cells. Using a vector system involving a designed repressor with zinc finger binding domains and the herpes simplex virus thymidine kinase (HSV-TK) "suicide gene," we demonstrate Smad4-responsive regulation of HSV-TK expression and consequent altered susceptibility to the prodrug ganciclovir (GCV). In pancreatic tumor cell lines stably transfected with the vector system, a robust differential of HSV-TK expression and GCV toxicity was attained depending on the presence or absence of cotransfected Smad4. In matched colon tumor cell lines lacking Smad4 or expressing physiological levels of Smad4, an adenoviral version of the vector system attained a significant degree of preferential killing of Smad4-negative tumor cells in response to GCV. These findings demonstrate the possibility of achieving selective killing of pancreatic and colon cells depending on their Smad4 status.

Indexed as

AdenoviridaeAntiviral AgentsCell LineCell Line, TumorDNA, SuperhelicalGanciclovirGene DeletionGenes, ReporterGenetic VectorsHCT116 CellsHumansKidneyLuciferasesModels, BiologicalPancreatic NeoplasmsPlasmidsAntiviral AgentsDNA, SuperhelicalGanciclovirLuciferasesProdrugsRepressor ProteinsSmad4 ProteinSMAD4 protein, humanThymidine Kinase

Identifiers

PMID18426856
PMCPMC2561925
OpenAlexW2057115641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.